Edition:
United States

INSYS Therapeutics Inc (INSY.O)

INSY.O on Consolidated Issue listed on NASDAQ Global Market

4.96USD
15 Feb 2019
Change (% chg)

$0.18 (+3.77%)
Prev Close
$4.78
Open
$4.89
Day's High
$4.97
Day's Low
$4.73
Volume
1,082,883
Avg. Vol
689,999
52-wk High
$11.65
52-wk Low
$3.35

Chart for

About

Insys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company's product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid... (more)

Overall

Beta: 0.85
Market Cap(Mil.): $644.09
Shares Outstanding(Mil.): 72.70
Dividend: --
Yield (%): --

Financials

  INSY.O Industry Sector
P/E (TTM): -- 69.44 33.70
EPS (TTM): -0.21 -- --
ROI: -5.71 8.92 14.45
ROE: -5.88 10.08 15.96

New York doctor pleads guilty to taking kickbacks from Insys

A New York doctor on Thursday pleaded guilty to accepting kickbacks from Insys Therapeutics Inc in exchange for prescribing a potent fentanyl spray called Subsys that is intended only for treating severe pain in cancer patients.

Feb 14 2019

Former Insys CEO says founder, executive fought over doctor payments

Insys Therapeutics Inc's former chief executive said on Wednesday that the company's founder angrily demanded, over the objections of another executive, a report showing how much the drugmaker was profiting from paying doctors who could prescribe its fentanyl spray Subsys.

Feb 13 2019

Former Insys CEO testifies against founder in opioid bribe trial

Insys Therapeutics Inc's former chief executive testified on Tuesday that onetime billionaire founder John Kapoor did not initially support the way the company induced doctors to prescribe its fentanyl spray Subsys and considered it too expensive.

Feb 12 2019

Nurse practitioner testifies she prescribed Insys' opioid for kickbacks

A former Connecticut nurse practitioner testified on Monday that her "greed" drove her to prescribe Insys Therapeutics Inc's addictive fentanyl spray Subsys for medically unnecessary purposes in exchange for thousands of dollars in kickbacks.

Feb 11 2019

Insys founder wanted 'return on investment' for paying doctors - witness

A former Insys Therapeutics Inc executive said on Monday that its founder sought a "positive return on investment" for paying doctors to speak at events about its fentanyl spray Subsys by requiring that they also prescribe its medication to patients.

Feb 04 2019

Insys executive gave doctor lap dance while promoting drug, witness says

BOSTON An ex-stripper who became a regional sales director at Insys Therapeutics Inc gave a doctor a lap dance at a Chicago club as the drugmaker pushed the doctor to prescribe its addictive fentanyl spray, a former Insys employee testified on Tuesday.

Jan 29 2019

Insys exec gave doctor lap dance while promoting drug, witness says

BOSTON, Jan 29 An ex-stripper who became a regional sales director at Insys Therapeutics Inc gave a doctor a lap dance at a Chicago club as the drugmaker pushed the doctor to prescribe its addictive fentanyl spray, a former Insys employee testified on Tuesday.

Jan 29 2019

'Greed' fueled Insys founder's opioid bribe scheme: prosecutor

BOSTON A lawyer for Insys Therapeutics Inc's one-time billionaire founder on Monday denied that he had any role in the U.S. opioid crisis as a federal prosecutor told jurors he ran a scheme to bribe doctors to prescribe an addictive fentanyl spray.

Jan 28 2019

UPDATE 3-'Greed' fueled Insys founder's opioid bribe scheme -prosecutor

BOSTON, Jan 28 A lawyer for Insys Therapeutics Inc's one-time billionaire founder on Monday denied that he had any role in the U.S. opioid crisis as a federal prosecutor told jurors he ran a scheme to bribe doctors to prescribe an addictive fentanyl spray.

Jan 28 2019

Insys founder, former execs face opioid kickback scheme trial

BOSTON, Jan 28 The one-time billionaire founder of Insys Therapeutics Inc and four other former executives and managers of the opioid drugmaker will face trial over charges they conspired to pay doctors bribes to prescribe patients an addictive fentanyl spray to boost sales.

Jan 28 2019

Earnings vs. Estimates